ClinicalTrials.gg
TerminatedNCT01320813Updated Mar 25, 2015

Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy

An interventional study of Robot-assisted thyroidectomy and Open thyroidectomy in Thyroid Nodule, Goiter and Thyroiditis, sponsored by Centre Hospitalier Universitaire de Nīmes. Terminated at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-03-25.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Treatment

Why this study was terminated
Unable to find enough patients who accept randomization of surgical procedures.
Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The main objective is to compare 12 month complication rates between a new surgical method for thyroidectomy (robot-assisted endoscopic thyroidectomy via a sub-clavical approach) and open thyroidectomy.

02

Conditions studied

  • Thyroid Nodule
  • Goiter
  • Thyroiditis
  • Graves Disease

Keywords

  • da vinci robot
  • Thyroidectomy
03

In context

Thyroid Nodule

207 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

This study's enrollment of 5 is below the median of 75 across 121 interventional studies indexed under Thyroid Nodule.

Browse Thyroid Nodule studies →

Lead sponsor

Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 90 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 12 months of follow-up
  • The patient is a candidate for total thyroidectomy because of a nodular pathology, a diffuse goiter, thyroiditis, or Basedow's disease
  • Patient has calcitoninemia \< 9 ng/pl
  • Patient has normal calcemia
  • Patient has PTH level between 5 ng/l and 75 ng/l
  • The subject has a normal laryngeal mobility

Exclusion criteria

Exclusion Criteria:

  • The patient is participating in another study
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant
  • The patient is breastfeeding
  • The patient is not available for 12 months of follow-up
  • Subject has a preoperative diagnosis of cancer on fine needle aspiration of the thyroid or cervical lymph node
  • Lymph node strongly suspected clinically and/or sonographically
  • The subject has an extension of substernal thyroid (diving goiter)
  • Family history of medullary thyroid cancer
  • The subject has a history of neck surgery
  • for general anesthesia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Robot arm

    Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.

    Procedure: Robot-assisted thyroidectomy

  • Active comparator
    Open surgery

    Patients in this arm will have a thyroidectomy using an open surgical technique.

    Procedure: Open thyroidectomy

Interventions

  • ProcedureRobot-assisted thyroidectomy

    Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.

  • ProcedureOpen thyroidectomy

    Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique

06

What researchers measure

Primary outcomes

  1. Presence/absence of complications (composite score)

    The per or post-operative occurrence of at least one of the following: postoperative hemorrhage requiring reintervention; cervical infection requiring antibiotics and/or surgical intervention; transient or persistent laryngeal paralysis; transient or persistent hypoparathyroidy (calcemia \< 1.9 µmol/l). Transiient means \< than and persistent means \>= 12 months.

    Time frame: 12 months

Secondary outcomes

  1. Incision size (mm)

    Length of incision in the open group, and sum of incision lengths in the robot group.

    Time frame: 12 months

  2. Patient satisfaction score

    Patient satisfaction as regards the incision scar measured using a visual analog scale from 0.0 to 10.0.

    Time frame: 12 months

  3. Presence/absence of conversion to open technique

    For patients in the robot arm: presence/absence of conversion to open technique.

    Time frame: 1 day

  4. Operating room prep time (min)

    Time in minutes necessary to prep the operating room

    Time frame: 1 day

  5. Presence/absence of per-operative complications

    Presence/absence of per-operative complications

    Time frame: 1 day

  6. Hospital stay (d)

    Length of hospitalization in days required after thyroidectomy

    Time frame: 7 to 15 days post-op

  7. Change in thyroglobulinemia (ng/l)

    Thyroglobulinemia at 12 months - Thryoglobulinemia as baseline

    Time frame: 12 months

  8. Change in calcemia (mg/l)

    Calcemia on Day 1 - Calcemia at inclusion

    Time frame: Day 1

  9. Change in calcemia (mg/l)

    Calcemia at the control visit (days 7 to 15) - Calcemia at inclusion

    Time frame: Day 7 to 15

  10. Change in calcemia (mg/l)

    Calcemia at 12 months - Calcemia at inclusion

    Time frame: 12 months

  11. Change in phosphoremia (mg/l)

    Phosphoremia at 1 day postop - Phosphoremia at inclusion

    Time frame: Day 1

  12. Change in phosphoremia (mg/l)

    Phosphoremia at control visit (days 7 to 15) - Phosphoremia at inclusion

    Time frame: Days 7 to 15

  13. Change in phosphoremia (mg/l)

    Phosphoremia at 12 months - Phosphoremia at inclusion

    Time frame: 12 months

  14. Change in parathormonemia (ng/l)

    Parathormonemia on Day 1 post-op - parathormonemia at inclusion

    Time frame: Day 1

  15. Change in parathormonemia (ng/l)

    Parathormonemia at control visit (days 7 to 15) - parathormonemia at inclusion

    Time frame: Days 7 to 15

  16. Change in parathormonemia (ng/l)

    Parathormonemia at 12 months - parathormonemia at inclusion

    Time frame: 12 months

  17. Visual Analog Pain Score

    Visual Analog Scale for pain (0.0 to 10.0)

    Time frame: Day 1

  18. Visual Analog Pain Score

    Visual Analog Scale for pain (0.0 to 10.0)

    Time frame: Days 7 to 15

  19. Visual Analog Pain Score

    Visual Analog Scale for pain (0.0 to 10.0)

    Time frame: 12 months

  20. Direct medical costs (€)

    Time frame: 12 months

  21. Indirect medical costs (€)

    Time frame: 12 months

07

Study locations

1 site
  • CHU de Nîmes - Hôpital Universitaire Carémeau
    Nîmes Cedex 09, Gard 30029, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2011
First posted
Mar 23, 2011
Start
Sep 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Mar 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01320813
Responsible party
Sponsor
First posted
Mar 23, 2011
Start date
Sep 2011
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Mar 25, 2015

Study contacts

Benjamin Lallemant, MD
principal investigator · Centre Hospitalier Universitaire de Nîmes

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion